Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

Abstract Background The efficacy and safety of opicapone, a once-daily catechol-O-methyltransferase inhibitor, have been established in two large randomized, placebo-controlled, multinational pivotal trials. Still, clinical evidence from routine practice is needed to complement the data from the piv...

Full description

Bibliographic Details
Main Authors: Heinz Reichmann, Andrew Lees, José-Francisco Rocha, Diogo Magalhães, Patrício Soares-da-Silva, the OPTIPARK investigators
Format: Article
Language:English
Published: BMC 2020-03-01
Series:Translational Neurodegeneration
Subjects:
Levodopa
Motor fluctuations
Open-label
Opicapone
Parkinson’s disease
Online Access:http://link.springer.com/article/10.1186/s40035-020-00187-1

Internet

http://link.springer.com/article/10.1186/s40035-020-00187-1

Similar Items